Filtered By:
Cancer: HER2

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 260 results found since Jan 2013.

HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.
Authors: Lu Y, Wang Y, Zhang M, Liu L, Li F, Zhang J, Ye M, Zhao H, Zhao J, Yan B, Yang A, Zhang R, Li X, Ren X Abstract Overexpression of human epidermal growth factor receptor type2 (HER2) is closely associated with aggressive progression and poor prognosis in non-small cell lung cancer (NSCLC). Here, we generated an EGFR-scFv-arginine nonamer peptide fusion protein (scFv-9R) as a cargo to deliver HER2 specific siRNA into HER2-positive NSCLC cells both in vitro and in vivo. HER2-siRNAs delivered by scFv-9R effeciently silenced HER2 expression in EGFR-positive NSCLC cells, and consequently resulted in G1 arrest an...
Source: Oncotarget - March 19, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
This study investigated the therapeutic potential of targeting the BAG-1 protein co-chaperone in trastuzumab-responsive or -resistant cells. In the METABRIC dataset, BAG-1 mRNA was significantly elevated in HER2+ breast tumors and predicted overall survival in a multivariate analysis (HR = 0.81; p = 0.022). In a breast cell line panel, BAG-1 protein was increased in HER2+ cells and was required for optimal growth as shown by siRNA knockdown. Overexpression of BAG-1S in HER2+ SKBR3 cells blocked growth inhibition by trastuzumab, whereas overexpression of a mutant BAG-1S protein (BAG-1S H3AB), defective in binding HSC70, pot...
Source: Oncotarget - March 10, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.
CONCLUSIONS: Our results support that PIN1 may be a valuable target to hit in cancer cells characterized by increased aggressive potential, overexpression of erbB receptor family members, and defective p53. PMID: 26917410 [PubMed - as supplied by publisher]
Source: Tumori - February 29, 2016 Category: Cancer & Oncology Tags: Tumori Source Type: research

Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
Authors: Gu S, Hu Z, Ngamcherdtrakul W, Castro DJ, Morry J, Reda MM, Gray JW, Yantasee W Abstract HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on patients. We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell ...
Source: Oncotarget - February 21, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Abstract P5-03-06: MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) receptor agonist, induces apoptotic cell death in breast cancer cells
In conclusion, MEDI3039 is a potent TRAIL receptor agonist in breast cancer cells and has potential as a cancer drug in breast cancer patients, especially those with TNBC basal B.Citation Format: Greer YE, Tice D, Lipkowitz S. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) receptor agonist, induces apoptotic cell death in breast cancer cells. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-03-06.
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Greer, Y., Tice, D., Lipkowitz, S. Tags: Poster Session Abstracts Source Type: research

Abstract P5-04-17: From transcriptome meta-analysis to targeted therapies in triple negative breast cancer
Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that urgently requires the identification and approval of novel targeted therapies. Even for breast cancer subtypes that have approved targeted therapies such as tamoxifen in ER+ and herceptin in HER2+ patients, there are a proportion of patients that do not respond to these therapies or develop resistance and succumb to metastatic recurrence. Thus, there is a clinical need to identify patients who do not benefit from current standard therapies and developing new strategies for therapy for non-responsive patients across all breast cancer subtypes.We hypothe...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Rozali, E., Al-Ejeh, F. Tags: Poster Session Abstracts Source Type: research

Abstract P5-08-22: DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer
Conclusions. Our findings suggest that DUSP4 is involved in the development of trastuzumab resistance in HER2 positive BC.Citation Format: Györffy B, Munkacsy G, Esteva FJ, Miquel TP, Menyhart O. DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-08-22.
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Gyorffy, B., Munkacsy, G., Esteva, F., Miquel, T., Menyhart, O. Tags: Poster Session Abstracts Source Type: research

Abstract PD2-06: Inhibition of 3-phosphoinositide dependent protein kinase 1 (PDK1) synergizes with CDK4/6 inhibitors against ER-positive breast cancer
Conclusions: These data support a critical role of PDK1 in mediating acquired resistance to CDK4/6 inhibitors in ER+ breast cancer cells. Co-targeting of the PDK1 and CDK4/6 pathways may overcome resistance to CDK4/6 inhibitors and is worthy of further translational and clinical investigation in patients with ER+ breast cancer.Citation Format: Jansen VM, Bhola NE, Bauer JA, Formisano L, Moore P, Koch J, Arteaga CL. Inhibition of 3-phosphoinositide dependent protein kinase 1 (PDK1) synergizes with CDK4/6 inhibitors against ER-positive breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Anton...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Jansen, V., Bhola, N., Bauer, J., Formisano, L., Moore, P., Koch, J., Arteaga, C. Tags: Poster Discussion Abstracts Source Type: research

Abstract S3-03: Nuclear FGFR1 interaction with estrogen receptor (ER) {alpha} is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer
Conclusions: These data support a critical role of ER and FGFR1 interaction in endocrine resistance in ER+/FGFR1-amplified breast cancer. Targeting of FGFR1 in combination with antiestrogens may abrogate resistance to endocrine therapy in these tumors and is worthy of clinical investigation.Citation Format: Formisano L, Young CD, Bhola NE, Bulen B, Estrada VM, Wagle N, Van Allen E, Red Brewer ML, Jansen VM, Guerrero AL, Giltnane JM, Strcker T, Arteaga CL. Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer. [abstract]. In: Proceedi...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Formisano, L., Young, C., Bhola, N., Bulen, B., Estrada, V., Wagle, N., Van Allen, E., Red Brewer, M., Jansen, V., Guerrero, A., Giltnane, J., Strcker, T., Arteaga, C. Tags: General Session Abstracts Source Type: research

Abstract P3-06-15: Notch3 as a predictor of GSI sensitivity in distinct subtypes of triple negative breast cancer
Conclusions: GSI acts through Notch3 in two TNBC subtypes and combination of chemotherapy with Notch inhibition results in a better outcome as compared to either drug alone. Future experiments would elucidate the role of Notch3 inhibition in targeting cancer stem cells post chemotherapy treatment in different subtypes of TNBC.Citation Format: Shah D, Osipo C. Notch3 as a predictor of GSI sensitivity in distinct subtypes of triple negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Shah, D., Osipo, C. Tags: Poster Session Abstracts Source Type: research

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.
Authors: Palanca-Wessels MC, Booth GC, Convertine AJ, Lundy BB, Berguig GY, Press MF, Stayton PS, Press OW Abstract The therapeutic potential of RNA interference (RNAi) has been limited by inefficient delivery of short interfering RNA (siRNA). Tumor-specific recognition can be effectively achieved by antibodies directed against highly expressed cancer cell surface receptors. We investigated the utility of linking an internalizing streptavidin-conjugated HER2 antibody to an endosome-disruptive biotinylated polymeric nanocarrier to improve the functional cytoplasmic delivery of siRNA in breast and ovarian cancer cell...
Source: Oncotarget - February 4, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
Authors: Li K, Ying M, Feng D, Chen Y, Wang J, Wang Y Abstract Triple-negative breast cancer (TNBC) is a special subtype of breast cancer, which is characterized by the negative form of estrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor 2 (HER2). TNBC accounts for ~15% of all breast cancer forms, and often leads to high mortality and poor prognosis. Structural maintenance of chromosome 1 (SMC1) is a subunit of the cohesion protein complex. Brachyury is a protein that is encoded by the T gene in humans, which is a transcription factor within the T-box complex of genes. ...
Source: Oncology Reports - January 21, 2016 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Abstract C26: Development of selective MELK kinase inhibitors for breast cancer treatment
In this study, we are reporting development of a series of selective MELK kinase inhibitors. Synthesized compounds exert excellent selectivity and potency in MELK inhibition in a low nanomolar range. Therapeutic effect of the compounds was investigated in the panel of breast cancer cell lines with different genetic background as well as with different MELK kinase levels; it was shown that for some cell lines compounds induced cell death with nanomolar ED50 values. The compound's effect on the proliferation and in the colony formation assay was also investigated. Taken altogether, the presented data supports our rationale o...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Kowalczyk, P., Węgrzyn, P., Prokopowicz, M., Knop, M., Mazur, K., Dziedzic, K., Gluza, K., Knop, M., Dziedzic, K., Mazur, K., Radzimierski, A., Commandeur, C., Zawadzka, M., Bloudoff, K., Vaillancourt, F., Larsen, N., Wang, J., Reynolds, D., Ito, D Tags: Cancer Stem Cells: Poster Presentations - Proffered Abstracts Source Type: research

Abstract A62: PARP-1 regulates NF-{kappa}B-mediated IL-8 expression in HER2 positive breast cancer
Conclusions:Trastuzumab resistant HER2+ breast cancer cells remain sensitive to PARP inhibition. Further, PARP-1 regulates the expression of IL-8, an NF-B regulated gene. These results suggest that inhibition of the interaction between PARP-1 and the NF-B signaling pathway may be a potential mechanism behind the sensitivity to PARPi in HER2+ trastuzumab resistant breast cancer cells.Citation Format: Monicka E. Wielgos, Rajani Rajbhandari, Susan Nozell, C. Kent Osborne, Rachel Schiff, Eddy S. Yang. PARP-1 regulates NF-B-mediated IL-8 expression in HER2 positive breast cancer. [abstract]. In: Proceedings of the AACR-NCI-EORT...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Wielgos, M. E., Rajbhandari, R., Nozell, S., Osborne, C. K., Schiff, R., Yang, E. S. Tags: EGFR / Her2: Poster Presentations - Proffered Abstracts Source Type: research

Abstract LB-B02: Acquisition of stem cell-like properties accompanying with Src family kinase/Focal adhesion kinase activation contributes to acquired resistance to afatinib in lung cancer cells
Conclusions] Together, our present study presents that increase of cancer stem like cells and SFK/FAK activation could be a mechanism responsible for acquired resistance to afatinib. We would further discuss the association of ALDH1 expression and SFK/FAK activation with afatinib resistance in lung cancer.Citation Format: Yuichi Murakami, Kahori Sonoda, Koichi Azuma, Kosuke Watari, Michihiko Kuwano, Mayumi Ono. Acquisition of stem cell-like properties accompanying with Src family kinase/Focal adhesion kinase activation contributes to acquired resistance to afatinib in lung cancer cells. [abstract]. In: Proceedings of the A...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Murakami, Y., Sonoda, K., Azuma, K., Watari, K., Kuwano, M., Ono, M. Tags: Drug Resistance and Modifiers: Poster Presentations - Proffered Abstracts Source Type: research